M Demers, DD Wagner - Seminars in thrombosis and …, 2014 - thieme-connect.com
Neutrophils have long been known as innate immune cells that phagocytose and kill pathogens and mount inflammatory responses protecting the host from infection. In the past …
The majority of patients with cancer undergo at least one surgical procedure as part of their treatment. Severe postsurgical infection is associated with adverse oncologic outcomes; …
M Garley, E Jabłońska, D Dąbrowska - Tumor Biology, 2016 - Springer
Many aspects of neutrophil hyperactivity and its role in numerous immune responses still remain a mystery. A new neutrophil mechanism was discovered recently, ie, the formation of …
T Lu, SD Kobayashi, MT Quinn, FR DeLeo - Frontiers in immunology, 2012 - frontiersin.org
Neutrophils constitute a critical part of innate immunity and are well known for their ability to phagocytose and kill invading microorganisms. The microbicidal processes employed by …
S Koizume, Y Miyagi - World journal of clinical oncology, 2014 - ncbi.nlm.nih.gov
Breast cancer is a leading cause of cancer death in women, worldwide. Fortunately, breast cancer is relatively chemosensitive, with recent advances leading to the development of …
LY Basyreva, EV Voinova, AA Gusev… - Materials Science and …, 2020 - Elsevier
Venous thromboembolism is a frequent complication occurring in patients suffering from neoplastic diseases. Since neutrophil extracellular traps (NETs) play an important role both …
M Garley, D Dziemiańczyk-Pakieła, K Grubczak… - Journal of …, 2018 - ncbi.nlm.nih.gov
Taking into account the previously reported relationship between inflammation and carcinogenesis, and the scant amount of data concerning the role of neutrophil extracellular …
Ixolaris is a potent tick salivary anticoagulant that binds coagulation factor Xa (FXa) and zymogen FX, with formation of a quaternary tissue factor (TF)/FVIIa/FX (a)/Ixolaris inhibitory …
M Zangari, T Berno, F Zhan, G Tricot… - Seminars in thrombosis …, 2012 - thieme-connect.com
The introduction of immunomodulatory drugs (IMiDs) has improved clinical outcome in patients with multiple myeloma (MM). However, their use has been associated with a higher …